Publications and Presentations

Presentation at the 2022 SITC Annual Meeting

Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysis

Presentation at the 2022 AACR Annual Meeting

AXA-042 – a novel systemic TLR2/6 agonist for anti-tumor therapy